## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.2% below STRENGTH zone (4.0-10.0%); PEG 2.48 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($79.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Thrivent Financial for Lutherans Purchases 49,601 Shares of GE HealthCare Technologies Inc. $GEHC**
- Source: MarketBeat | 20251220T111613 | Somewhat-Bullish | Relevance: 100%
- Thrivent Financial for Lutherans significantly increased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 229.3% in the second quarter, acquiring 49,601 additional shares, bringing its total holdings to 71,233 shares valued at $5.28 million. Other institutional investors, such as Dodge & Cox and Norges Bank, also made substantial moves in GEHC stock, with institutional investors now owning 82.06% of the company. GE HealthCare, with a market cap of $37.76 billion, recently exceeded EPS and revenue estimates, provided guidance for FY2025 EPS, and maintains a "Moderate Buy" consensus analyst rating.

**2. 357,638 Shares in GE HealthCare Technologies Inc. $GEHC Acquired by Wedge Capital Management L L P NC**
- Source: MarketBeat | 20251221T123511 | Bullish | Relevance: 100%
- Wedge Capital Management L L P NC has acquired a new stake of 357,638 shares in GE HealthCare Technologies Inc. (NASDAQ:GEHC), valued at approximately $26.9 million. This purchase represents about 0.08% of the company's shares. Other institutional investors like Vanguard Group Inc. and Dodge & Cox also increased their holdings in GE HealthCare, indicating strong institutional interest.

**3. GE HealthCare Technologies Inc. $GEHC Stock Position Lowered by Texas Permanent School Fund Corp**
- Source: MarketBeat | 20251221T103757 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 34.8% in Q2, selling 17,157 shares and retaining 32,207 shares valued at approximately $2.39 million. Despite this, analyst sentiment remains mixed-to-positive with a "Moderate Buy" consensus rating and an average price target of $87.09, while the company recently exceeded EPS estimates and provided positive FY2025 guidance. GE HealthCare, with a market cap of $37.8 billion and a P/E of 17.1, also announced a quarterly dividend.

**4. Is Boston Scientific (BSX) One of the Best Healthcare AI Stocks to Buy Now?**
- Source: Finviz | 20251223T010913 | Neutral | Relevance: 63%
- TD Cowen has reaffirmed a Buy rating on Boston Scientific (BSX), naming it their "Best Idea for 2026" due to its strong growth story in the medical devices sector. The firm expects over 10% organic sales growth annually and double-digit EPS growth, driven by key products like Farapulse and Watchman. Boston Scientific also leverages AI in its medical devices to enhance imaging, predictive analytics, and remote monitoring.

**5. Is IRADIMEDâ€™s US$0.50 Special Dividend Reshaping the Investment Case for IRMD?**
- Source: Simply Wall Street | 20251220T220855 | Neutral | Relevance: 62%
- IRADIMED Corporation recently declared a special cash dividend of US$0.50 per share, payable on December 30, 2025. This one-off payout underscores the company's financial flexibility and its ability to return excess cash to shareholders, reinforcing its investment narrative focused on MRI-compatible devices and recurring revenue. While the special dividend highlights balance sheet strength, the company's future investment case still heavily relies on the successful adoption of its 3870 pump and managing concentration risk within its product lineup.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.48 elevated, pricing in significant growth expectations. Forward P/E 17.0x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.3B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.48 |
| Forward P/E | 17.0 |
| Current P/E | 18.4 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.2% to 1.2% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.8pp (needs >4.0% for momentum thesis). MRS_5 (-0.0%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.23% (CS: 60) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | -0.23 | Bearish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.080x | Above |
| vs SMA200 | 1.127x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.94
- **Stop Loss:** $79.92 (4.8% risk)
- **Target:** $87.96 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 298
- **Position Value:** $25,014.12
- **Portfolio %:** 25.01%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*